A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Suzanne McGoldrick, MD, MPH
Seagen Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California at San Francisco
San Francisco, California, United States
- Yale Cancer Center
New Haven, Connecticut, United States
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
- Mount Sinai Medical Center
New York, New York, United States
- Levine Cancer Institute
Charlotte, North Carolina, United States
- University of Pennsylvania / Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Feb 2018
- Primary completion
- 23 Aug 2019
- Completion
- 23 Aug 2019
- Last update posted
- 18 Sept 2019
- Registered enrollment
- 14
- Registry id
- NCT03379584
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.